ArticlePharmaceutics2012
Signal detection and monitoring based on longitudinal healthcare data.
Article in Pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Methods for drug safety signal detection using routinely collected observational electronic health care data: A systematic review.Pharmacoepidemiology and drug safety · 2023Pooled it
- Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.British journal of clinical pharmacology · 2015Pooled it
- Misclassification bias in chronic disease case ascertainment algorithms: a reclassification approach.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2026Article
- Active Surveillance for COVID-19 Vaccine Safety Using Sequential Analysis in Korea: Population-Based Retrospective Observational Study.JMIR public health and surveillance · 2026Observational
- Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.International journal of molecular sciences · 2026Article
- Optimal Significance Levels and Sample Sizes for Signal Detection Methods Based on Non-constant Hazards.Drug safety · 2024Article
- Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.Frontiers in pharmacology · 2024Article
- A discovery and verification approach to pharmacovigilance using electronic healthcare data.Frontiers in pharmacology · 2024Article
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.Pharmaceuticals (Basel, Switzerland) · 2023Article
- A New Drug Safety Signal Detection and Triage System Integrating Sequence Symmetry Analysis and Tree-Based Scan Statistics with Longitudinal Data.Clinical epidemiology · 2023Article
- Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS).Pharmaceuticals (Basel, Switzerland) · 2022Article
- A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data.Frontiers in pharmacology · 2022Article
- Subset Analysis for Screening Drug-Drug Interaction Signal Using Pharmacovigilance Database.Pharmaceutics · 2020Article
- Propensity score-adjusted three-component mixture model for drug-drug interaction data mining in FDA Adverse Event Reporting System.Statistics in medicine · 2020Article
- Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review.BMC medical research methodology · 2019Article
- Patchwork of contrasting medication cultures across the USA.Nature communications · 2018Article
- Causality Patterns for Detecting Adverse Drug Reactions From Social Media: Text Mining Approach.JMIR public health and surveillance · 2018Article
- An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence.Scientific reports · 2018Article
- A Semantic Transformation Methodology for the Secondary Use of Observational Healthcare Data in Postmarketing Safety Studies.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-marketing detection and surveillance of potential safety hazards are crucial tasks in pharmacovigilance. To uncover such safety risks, a wide set of techniques has been developed for spontaneous reporting data and, more recently, for longitudinal data. This paper gives a broad overview of the signal detection process and introduces some types of data sources typically used. The most commonly applied signal detection algorithms are presented, covering simple frequentistic methods like the proportional reporting rate or the reporting odds ratio, more advanced Bayesian techniques for spontaneous and longitudinal data, e.g., the Bayesian Confidence Propagation Neural Network or the Multi-item Gamma-Poisson Shrinker and methods developed for longitudinal data only, like the IC temporal pattern detection. Additionally, the problem of adjustment for underlying confounding is discussed and the most common strategies to automatically identify false-positive signals are addressed. A drug monitoring technique based on Wald's sequential probability ratio test is presented. For each method, a real-life application is given, and a wide set of literature for further reading is referenced.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.